EGF RECEPTOR IN SMOOTH MUSCLE CELL FUNCTION

$266,433P01FY2001HLNIH

University Of Washington, Seattle WA

Investigators

Linked publications & trials

Paper 29891514 Paper 29499356 Paper 26747209 Paper 24726364 Paper 24719328 Paper 24614953 Paper 24513039 Paper 24401530 Paper 24046373 Paper 24043629 Paper 23584255 Paper 23479224 Paper 23354118 Paper 23192608 Paper 23159731 Paper 23022999 Paper 22975374 Paper 22936797 Paper 22810951 Paper 22394260 Paper 22351750 Paper 22308341 Paper 22170060 Paper 22155153 Paper 22011752 Paper 21920460 Paper 21868708 Paper 21628404 Paper 21550016 Paper 21518860 Paper 21512158 Paper 21474830 Paper 21441139 Paper 21411713 Paper 21150327 Paper 20974999 Paper 20664908 Paper 20228832 Paper 20167938 Paper 20142100 Paper 20053468 Paper 20042606 Paper 19934003 Paper 19717812 Paper 19635906 Paper 19581629 Paper 19549927 Paper 19401397 Paper 19357791 Paper 19344785 Paper 19286646 Paper 19145240 Paper 19116209 Paper 19110081 Paper 19105036 Paper 19029122 Paper 18988796 Paper 18948257 Paper 18818413 Paper 18644228 Paper 18596265 Paper 18502305 Paper 18430750 Paper 18209078 Paper 17804111 Paper 17717292 Paper 17673516 Paper 17617562 Paper 17563062 Paper 17478729 Paper 17303781 Paper 17303772 Paper 17226775 Paper 17226774 Paper 17214992 Paper 17174314 Paper 17095732 Paper 17046999 Paper 16939572 Paper 16888388 Paper 16839865 Paper 16709944 Paper 16565325 Paper 16492728 Paper 16385080 Paper 16374516 Paper 16373605 Paper 16210729 Paper 16183915 Paper 16127167 Paper 16118212 Paper 16110480 Paper 15994327 Paper 15983222 Paper 15978611 Paper 15964815 Paper 15949549 Paper 15834121 Paper 15820209 Paper 15731493

Abstract

Heparin and related heparan sulfate glycosaminoglycans inhibit smooth muscle cell (SMC) proliferation and migration. This observation is of significance because heparan sulfate proteoglycans may play a role in regulating the growth state of SMCs in the normal arterial wall. Heparin inhibits SMC activation by thrombin and serum but not PDGF-BB. In preliminary experiments, we have shown that thrombin signaling is mediated in part by heparin-binding EGF-like growth factor (HB-EGF), activation of the EGF receptor (EGFR), and is not blocked by heparin. The primary objective of this research program is to test three hypotheses: 1. EGFR activation is required for SMC migration in vitro and in vivo; 2. PDGF-BB and thrombin utilize different mechanisms for EGFR transactivation; 3. EGFR activation induces the expression of heparan sulfate proteoglycans that then modulate EGFR function. We propose a combined in vitro and in vivo approach using cultured baboon and rat SMCs, the balloon-injured rat carotid artery, and pharmacological strategies for modulating HB-EGF, EGFR, PDGFR, and thrombin receptor function.

View original record on NIH RePORTER →